

# Dementia - Pipeline Review, H2 2020

<https://marketpublishers.com/r/D70009828BBEN.html>

Date: August 2020

Pages: 537

Price: US\$ 2,000.00 (Single User License)

ID: D70009828BBEN

## Abstracts

Dementia - Pipeline Review, H2 2020

### Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dementia - Pipeline Review, H2 2020, provides an overview of the Dementia (Central Nervous System) pipeline landscape.

Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation and cardiovascular diseases.

### Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dementia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-

Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 10, 22, 25, 2, 67, 29 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 1, 1, 12, 5 and 1 molecules, respectively.

Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Dementia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA)

and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Dementia (Central Nervous System)

## **Reasons to Buy**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Dementia - Overview

Dementia - Therapeutics Development

Dementia - Therapeutics Assessment

Dementia - Companies Involved in Therapeutics Development

Dementia - Drug Profiles

Dementia - Dormant Projects

Dementia - Discontinued Products

Dementia - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Dementia, H2 2020  
Number of Products under Development by Companies, H2 2020  
Number of Products under Development by Universities/Institutes, H2 2020  
Products under Development by Companies, H2 2020  
Products under Development by Universities/Institutes, H2 2020  
Products under Development by Universities/Institutes, H2 2020 (Contd..1), H2 2020  
Number of Products by Stage and Target, H2 2020  
Number of Products by Stage and Target, H2 2020 (Contd..1), H2 2020  
Number of Products by Stage and Target, H2 2020 (Contd..2), H2 2020  
Number of Products by Stage and Mechanism of Action, H2 2020  
Number of Products by Stage and Mechanism of Action, H2 2020 (Contd..1), H2 2020  
Number of Products by Stage and Mechanism of Action, H2 2020 (Contd..2), H2 2020  
Number of Products by Stage and Route of Administration, H2 2020  
Number of Products by Stage and Molecule Type, H2 2020  
Dementia - Pipeline by AbbVie Inc, H2 2020  
Dementia - Pipeline by Acadia Pharmaceuticals Inc, H2 2020  
Dementia - Pipeline by Actinogen Medical Ltd, H2 2020  
Dementia - Pipeline by AcuraStem Inc, H2 2020  
Dementia - Dormant Projects, H2 2020  
Dementia - Discontinued Products, H2 2020  
Dementia - Discontinued Products, H2 2020 (Contd..1), H2 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Dementia, H2 2020  
Number of Products under Development by Companies, H2 2020  
Number of Products under Development by Universities/Institutes, H2 2020  
Number of Products by Top 10 Targets, H2 2020  
Number of Products by Stage and Top 10 Targets, H2 2020  
Number of Products by Top 10 Mechanism of Actions, H2 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020  
Number of Products by Top 10 Routes of Administration, H2 2020  
Number of Products by Stage and Top 10 Routes of Administration, H2 2020  
Number of Products by Top 10 Molecule Types, H2 2020  
Number of Products by Stage and Top 10 Molecule Types, H2 2020

### COMPANIES MENTIONED

AbbVie Inc  
Acadia Pharmaceuticals Inc  
Actinogen Medical Ltd  
AcuraStem Inc  
Adamed Sp zoo  
ADEL Inc  
AFFiRiS AG  
AgeneBio Inc  
Aibios Co Ltd  
Alector Inc  
Alkermes Plc  
Allergan Ltd  
AlphaCognition Inc  
Alterity Therapeutics Ltd  
Anavex Life Sciences Corp  
Annovis Bio Inc  
Applied Genetic Technologies Corp  
Aprinoia Therapeutics Inc  
AriBio  
Arkuda Therapeutics Inc  
Arvinas Inc

Asceneuron SA  
Avanir Pharmaceuticals Inc  
Axon Neuroscience SE  
Axovant Gene Therapies Ltd  
Axsome Therapeutics Inc  
Bicycle Therapeutics Plc  
Biogen Inc  
BioXcel Therapeutics Inc  
Boehringer Ingelheim International GmbH  
Cellular Biomedicine Group Ltd  
Cennerv Pharma (S) Pte Ltd  
Cerevel Therapeutics LLC  
ChunLab Inc  
Cortice Biosciences Inc  
CSPC NBP Pharmaceutical Co Ltd  
Curyx Bio Inc  
Cyclerion Therapeutics Inc  
Dadang & BIO Co Ltd  
Daewoong Pharmaceutical Co Ltd  
Denali Therapeutics Inc  
DiaMedica Therapeutics Inc  
Dongkook Pharmaceutical Co Ltd  
Dr. August Wolff GmbH & Co KG Arzneimittel  
Echo Pharmaceuticals BV  
EIP Pharma LLC  
Eisai Co Ltd  
Eli Lilly and Co  
Ensol Biosciences Inc  
Enterin Inc  
EVER Neuro Pharma GmbH  
Galimedix Therapeutics Ltd  
Gismo Therapeutics Inc  
Guangzhou Magpie Pharmaceutical Co Ltd  
GW Pharmaceuticals Plc  
HanAll Biopharma Co Ltd  
Hemostemix Inc  
HSRx Group  
Hyundai Pharma Co Ltd  
Immungenetics AG

ImStar Therapeutics Inc  
Inhibikase Therapeutics Inc  
IntraBio Ltd  
IRLAB Therapeutics AB  
Johnson & Johnson  
Kogenix Therapeutics Inc  
Korea Pharma Co Ltd  
Kwang Dong Pharmaceutical Co Ltd  
Lachesis Biosciences Ltd  
Luye Pharma Group Ltd  
Mediforum Pharmaceutical Inc  
MediPost Co Ltd  
Merck & Co Inc  
Merz Pharma GmbH & Co KgaA  
MGC Pharmaceuticals Ltd  
Neuraltus Pharmaceuticals Inc  
Neurimmune Holding AG  
Neurokine Therapeutics  
NeuroScientific Biopharmaceuticals Ltd  
NeuroTau Inc  
NLS Pharma Group  
Novartis AG  
Oligomerix inc  
Orchard Therapeutics Plc  
Oryzon Genomics SA  
Otsuka Pharmaceutical Co Ltd  
P2D Inc  
Pacific Northwest Biotechnology LLC  
Palisades Therapeutics  
Park Active Molecules  
Passage Bio Inc  
Plico Biotech Inc  
Prediction BioSciences SAS  
Prevail Therapeutics Inc  
ProMIS Neurosciences Inc  
Prothena Corp Plc  
Psy Therapeutics Inc  
QurAlis Corporation  
Reborna Biosciences Inc



Resverlogix Corp  
Reven Pharmaceuticals Inc  
Samus Therapeutics Inc  
Sinfonia Biotherapeutics Inc  
SK Chemicals Co Ltd  
Stemmedica Cell Technologies Inc  
Sun Pharma Advanced Research Company Ltd  
Suven Life Sciences Ltd  
SyneuRx International Corp  
T3D Therapeutics Inc  
TauRx Therapeutics Ltd  
Theranexus SAS  
Time Therapeutics Inc  
Towa Pharmaceutical Co Ltd  
Tranquis Therapeutics Inc  
UniQure NV  
Verge Genomics Inc  
Voyager Therapeutics Inc  
Wave Life Sciences Ltd  
WhanIn Pharmaceutical Co Ltd

## I would like to order

Product name: Dementia - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/D70009828BBEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D70009828BBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970